Biologics quality testing
Faster, safer, animal free.
PathoQuest drives innovation in quality testing to deliver new biotherapies rapidly and safely to patients.
Why PARTNER WITH PathoQuest?
At PathoQuest, we understand that you need to develop your innovative biologics safely and timely in a complex testing environment. PathoQuest provides a pioneering next generation sequencing (NGS) approach to biologics characterization and release testing for global biopharmaceutical and emerging biologics companies.
With a proven track record in the provision of regulated contract research services, PathoQuest offers a team of 50 genomic experts based in France and the U.S. Our expert CRO team are readily available to support with rapid and robust quality controlled (QC) testing at GMP and non-GMP level.
Let’s work together to transform the future of biologic therapies and treatments to transform patient lives.
Modalities
mAbs and Recombinants
Bacterial and mammalian produced proteins, hormones and peptides
READ MORE
Viral Vectors
Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids
READ MORE
Cell Therapies
Including gene modified, or unmodified stem cell therapies, allogeneic or autologous
READ MORE
Vaccines
Inactivated, live-attenuated, recombinant, RNA and viral vector products
READ MORE
RNA
Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing
READ MORE
Cultivated Meat
Engineered cells and tissues cultured in more ethical in vitro environments
READ MORE
3Rs
Next generation sequencing is the ethical alternative to in vivo testing for the quality control testing of biologics.
PathoQuest, in partnership with Charles River Laboratories, is the first CRO to conclusively demonstrate the superiority of NGS over conventional in vivo biosafety testing and characterization.
3Rs
Next generation sequencing is the ethical alternative to in vivo testing for the quality control testing of biologics.
PathoQuest, in partnership with Charles River Laboratories, are the first CRO to conclusively demonstrate the superiority of NGS over conventional in vivo biosafety testing and characterization.
SERVICES
Adventitious Virus Testing
Detection of viral contamination within the manufacturing process and beyond.
Identity Confirmation
Genetic characterization of viral and plasmid products for release.
nCats Integration Site Analysis
Characterisation of genetic modifications for clone selection, genetic stability and lot release
Cell Line Characterization
Biosafety screening and stability testing of manufacturing cells.
HLA Genotyping
Characterizing and screening for novel and emerging cell therapies.
In Vivo Replacement
NGS as an ethical alternative to animals in biosafety testing and characterization.
Raw Material Testing
Screening of high-risk inputs such as animal products and media.
READ MORE
READ MORE
READ MORE
SERVICES
Adventitious Virus Testing
Detection of viral contamination within the manufacturing process and beyond.
READ MORE
Identity Confirmation
Genetic characterization of viral and plasmid products for release.
READ MORE
Cell Line Characterization
Biosafety screening and stability testing of manufacturing cells.
READ MORE
HLA Genotyping
Characterizing and screening for novel and emerging cell therapies.
READ MORE
In Vivo Replacement
NGS as an ethical alternative to animals in biosafety testing and characterization.
READ MORE
Raw Material Testing
Screening of high-risk inputs such as animal products and media.
READ MORE
STRATEGIC PARTNERSHIPS
News and Events
Revised ICHQ5A(R2) is adopted: call for action in viral safety testing!
The updated ICHQ5A(R2) guideline adopted in November 2023 highlights the benefits of Next Generation Sequencing assays versus in vivo assays: 3.2.3: "NGS is encouraged as a replacement for in vivo assays because it can overcome the limitations of the breadth and...
Webinar Replay – Integration Site Analysis: An innovative method for faster, more certain clone selection & genetic stability testing
Listen to an archived version of our recent webinar which provided information on our new integration site analysis assay. The assay uses Cas9 targeted DNA cleavage combined with nanopore sequencing technology to comprehensively sequence the junction site. This assay...
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French Agency.
Substitution of in vitro and in vivo virus testing with PathoQuest NGS confirmed by French AgencyPathoQuest is pleased to announce that the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) have recently published their review of PathoQuest’s...
LOOK FOR US AT THESE UPCOMING MEETINGS
- BPI US West 2024 – March 11th-14th, San Diego, CA
- Swiss Biotech Days 2024 – April 22nd-24th, Basel, Switzerland
Contact us
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
E: contact@pathoquest.com
Sign up for our latest news
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
How can PathoQuest help?
U.S.
466 Devon Park Dr
Wayne, PA 19087
United States
France
+33 (0)1 70 82 17 90
Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France
E: contact@pathoquest.com
How can PathoQuest help?
Sign up for our latest news